Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84?μM to 7.3?μM.In Vitro: Vebicorvir (ABI-H0731) demonstrates inhibition of pgRNA, HBeAg, and HBsAg production, with EC50s of 2.68?μM, 4.95?μM, and 7.30?μM, respectively.
Vebicorvir (ABI-H0731) is an inhibitor of pgRNA encapsidation and rcDNA synthesis.
In Vivo: After i.v. administration, the drug rapidly distributes and decayes in a biphasic manner in all species tested. Plasma clearance values of ABI-H0731 were 8.05, 10.1, 14.7, and 4.86?ml/min/kg, representing 9, 16, 47, and 11% of liver blood flow, in mouse, rat, dog, and monkey, respectively.